3 results match your criteria: "UMIT TIROL - University for Health Sciences and Health Technology[Affiliation]"
Improving antibiotic prescribing - Recommendations for funding and pricing policies to enhance use of point-of-care tests.
Health Policy Open
December 2024
WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Pharmacoeconomics Department, Gesundheit Österreich GmbH (GÖG/Austrian National Public Health Institute), Stubenring 6, 1010 Vienna, Austria.
Introduction: Diagnostics can contribute to the improved quality of antibiotic prescribing. However, there is potential to enhance the use of point-of-care tests (POCTs) in general practice. This paper presents fit-for-purpose policy recommendations related to funding and pricing for POCTs applied for community-acquired acute respiratory tract infections (CA-ARTIs).
View Article and Find Full Text PDFThe assessment of quality of care of patients with type 2 diabetes mellitus in a population-based cohort in the District of Landeck in Austria.
Prim Care Diabetes
April 2024
Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health, Health Services Research and Health Technology Assessment, UMIT TIROL - University for Health Sciences and Health Technology, Hall in Tirol, Austria.
Introduction: Structured diabetes care based on evidence-based guidelines is one of the main strategies to improve glycemic control and to reduce long-term complications in diabetes mellitus.
Methods: This study is based on the "Diabetes-Landeck Cohort", a population-based cohort of patients with diabetes mellitus type 2 (T2DM). We assessed the quality of diabetes care and compared it between three groups of care units, that is, general practitioners (GP), diabetes specialists in private practice (DSPP), and hospitals (HOSP).
Barriers and Facilitators in Pricing and Funding Policies of European Countries That Impact the Use of Point-of-Care Diagnostics for Acute Respiratory Tract Infections in Outpatient Practices.
Diagnostics (Basel)
December 2023
WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Pharmacoeconomics Department, Gesundheit Österreich GmbH (Austrian National Public Health Institute/GÖG), 1010 Vienna, Austria.
Article Synopsis
- * The study examined barriers and facilitators to adopting these rapid diagnostics in five European countries, focusing on health technology assessment (HTA), pricing, and funding policies.
- * Key barriers include lack of evidence for HTA processes and absence of price regulation, while potential facilitators are reimbursement coverage and better compensation for doctors using these tests, indicating room for improvement in policies to encourage their use.